All the news articles and press releases in one place.

Search
Date / Time Source Ticker Company Sector Market Cap Announcement
26May17 20:31 GNW 0QLR:LON Novartis AG Health 208,186m Novartis receives FDA approval for expanded use of Zykadia® in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)
23May17 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis' new analyses reinforce the potential of Ultibro® Breezhaler® for COPD patients historically treated with steroids
19May17 12:47 GNW 0QLR:LON Novartis AG Health 208,186m Novartis receives positive CHMP opinion for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)
18May17 11:05 GNW 0QLR:LON Novartis AG Health 208,186m Novartis data at ASCO, ICML and EHA meetings demonstrate meaningful advancements in cancer care
17May17 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis Foundation and partners launch initiative to tackle hypertension and its root causes in low-income urban communities
11May17 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis celebrates 21st annual Community Partnership Day with over 24,500 associates volunteering in their local communities
04May17 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis exercises exclusive option agreement with Conatus for the treatment of NASH
28Apr17 16:30 GNW 0QLR:LON Novartis AG Health 208,186m Novartis receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM)
26Apr17 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Alcon announces EU launch of CyPass® Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma
25Apr17 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
25Apr17 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
24Apr17 21:30 GNW 0QLR:LON Novartis AG Health 208,186m Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada
24Apr17 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS
21Apr17 18:43 GNW 0QLR:LON Novartis AG Health 208,186m Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*
19Apr17 22:00 GNW 0QLR:LON Novartis AG Health 208,186m NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia
18Apr17 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis expands development programs for NASH through clinical collaboration with Allergan
18Apr17 06:10 GNW 0QLR:LON Novartis AG Health 208,186m Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
06Apr17 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
03Apr17 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis drug combination Tafinlar® + Mekinist® receives EU approval for BRAF V600-positive advanced non-small cell lung cancer (NSCLC)
29Mar17 21:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
29Mar17 21:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
23Mar17 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Alcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correction
22Mar17 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
22Mar17 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
21Mar17 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis
18Mar17 13:45 GNW 0QLR:LON Novartis AG Health 208,186m New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
13Mar17 19:08 GNW 0QLR:LON Novartis AG Health 208,186m Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
13Mar17 19:08 GNW 0QLR:LON Novartis AG Health 208,186m Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
13Mar17 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Sandoz announces winners of inaugural Healthcare Access Challenge (Sandoz HACk)
06Mar17 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
06Mar17 06:10 GNW 0QLR:LON Novartis AG Health 208,186m New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine
28Feb17 12:44 GNW 0QLR:LON Novartis AG Health 208,186m Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
24Feb17 12:07 GNW 0QLR:LON Novartis AG Health 208,186m Novartis receives positive CHMP opinion for Tafinlar® + Mekinist® in BRAF-positive non-small cell lung cancer (NSCLC) patients
23Feb17 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC
31Jan17 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC
26Jan17 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report
26Jan17 06:10 GNW 0QLR:LON Novartis AG Health 208,186m Alcon launches new trifocal toric intraocular lens for patients with astigmatism undergoing cataract surgery
25Jan17 17:31 GNW 0QLR:LON Novartis AG Health 208,186m NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2016
25Jan17 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
25Jan17 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
06Jan17 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders
20Dec16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc.
19Dec16 21:30 GNW 0QLR:LON Novartis AG Health 208,186m Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases
16Dec16 12:27 GNW 0QLR:LON Novartis AG Health 208,186m Novartis receives positive CHMP recommendation for Ilaris® to treat rare diseases in adults and children called Periodic Fever Syndromes
16Dec16 12:23 GNW 0QLR:LON Novartis AG Health 208,186m Novartis drug Votubia® recommended by CHMP for EU approval to treat refractory partial-onset seizures in patients with TSC
16Dec16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited
12Dec16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines
12Dec16 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)
12Dec16 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)
09Dec16 13:30 GNW 0QLR:LON Novartis AG Health 208,186m Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole
08Dec16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis' Ultibro® Breezhaler® improved lung function and COPD symptoms after direct switch from previous treatment
07Dec16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis' Lucentis® received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions
06Dec16 08:45 GNW 0QLR:LON Novartis AG Health 208,186m Novartis announces Zykadia® first-line study results showing 16.6 month progression-free survival in patients with ALK+ advanced NSCLC
05Dec16 18:30 GNW 0QLR:LON Novartis AG Health 208,186m Novartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna® from Glivec®
05Dec16 18:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work
05Dec16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product
04Dec16 00:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL
03Dec16 18:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study
29Nov16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda
21Nov16 06:20 GNW 0QLR:LON Novartis AG Health 208,186m Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)
21Nov16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis commends publication of major report which recommends broad use of dual bronchodilators to treat COPD
18Nov16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Innovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originator
16Nov16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer
15Nov16 18:00 GNW 0QLR:LON Novartis AG Health 208,186m New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths
14Nov16 06:20 GNW 0QLR:LON Novartis AG Health 208,186m Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis
14Nov16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain
14Nov16 00:01 GNW 0QLR:LON Novartis AG Health 208,186m Novartis improves ranking in 2016 Access to Medicine Index
01Nov16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer
01Nov16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer
31Oct16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis Wins Two Prestigious Prix Galien Foundation Awards; Gleevec® recognized as "Discovery of the Decade" for Best Pharmaceutical Product, Cosentyx® as Best Biotechnology Product
25Oct16 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
25Oct16 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
17Oct16 22:00 GNW 0QLR:LON Novartis AG Health 208,186m Alcon launches the CyPass® Micro-Stent at the American Academy of Ophthalmology (AAO) 2016 annual meeting
09Oct16 07:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival beyond 18 months in Phase II study
08Oct16 07:30 GNW 0QLR:LON Novartis AG Health 208,186m Novartis' Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow up
08Oct16 07:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care
03Oct16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis reports over half of psoriasis patients do not reach the achievable treatment goal of clear skin in largest global survey
01Oct16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis late-breaking data show Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients
28Sep16 21:30 GNW 0QLR:LON Novartis AG Health 208,186m Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine
28Sep16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Sandoz invites young entrepreneurs to enter Sandoz HACk, a global competition to help solve healthcare access challenges
23Sep16 16:51 GNW 0QLR:LON Novartis AG Health 208,186m Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions
23Sep16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia® in untreated adult ALK+ NSCLC patients
21Sep16 22:00 GNW 0QLR:LON Novartis AG Health 208,186m Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs
19Sep16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients
18Sep16 21:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients
17Sep16 10:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients
15Sep16 21:30 GNW 0QLR:LON Novartis AG Health 208,186m Novartis presents new positive data at EHMTIC showing AMG 334 significantly reduces monthly migraine days in chronic migraine
15Sep16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis Foundation showcases progress in leprosy elimination programs at 19th International Leprosy Congress
09Sep16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m New Novartis point of care Niji(TM) System may provide earlier diagnosis of severe allergic asthma and faster treatment decisions
08Sep16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Alcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experience
03Sep16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis' Ultibro® Breezhaler® consistently more effective than Seretide®* in reducing COPD flare-ups across different patient groups
31Aug16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment
29Aug16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis convenes experts to discuss new technologies in healthcare at Novartis International BioCamp
25Aug16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS
25Aug16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS
15Aug16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Six leading scientists to receive prestigious Novartis Prizes for Immunology at 16th International Congress of Immunology
03Aug16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
02Aug16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma
19Jul16 06:01 GNW 0QLR:LON Novartis AG Health 208,186m Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
19Jul16 06:01 GNW 0QLR:LON Novartis AG Health 208,186m Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
Date / Time Source Company % Chg
26May17 20:31 GNW Novartis AG 0.70%
Novartis receives FDA approval for expanded use of Zykadia® in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)
23May17 06:15 GNW Novartis AG 0.70%
Novartis' new analyses reinforce the potential of Ultibro® Breezhaler® for COPD patients historically treated with steroids
19May17 12:47 GNW Novartis AG 0.70%
Novartis receives positive CHMP opinion for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)
18May17 11:05 GNW Novartis AG 0.70%
Novartis data at ASCO, ICML and EHA meetings demonstrate meaningful advancements in cancer care
17May17 06:15 GNW Novartis AG 0.70%
Novartis Foundation and partners launch initiative to tackle hypertension and its root causes in low-income urban communities
11May17 06:15 GNW Novartis AG 0.70%
Novartis celebrates 21st annual Community Partnership Day with over 24,500 associates volunteering in their local communities
04May17 06:15 GNW Novartis AG 0.70%
Novartis exercises exclusive option agreement with Conatus for the treatment of NASH
28Apr17 16:30 GNW Novartis AG 0.70%
Novartis receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM)
26Apr17 06:15 GNW Novartis AG 0.70%
Alcon announces EU launch of CyPass® Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma
25Apr17 06:00 GNW Novartis AG 0.70%
Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
25Apr17 06:00 GNW Novartis AG 0.70%
Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
24Apr17 21:30 GNW Novartis AG 0.70%
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada
24Apr17 06:15 GNW Novartis AG 0.70%
Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS
21Apr17 18:43 GNW Novartis AG 0.70%
Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*
19Apr17 22:00 GNW Novartis AG 0.70%
NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia
18Apr17 06:15 GNW Novartis AG 0.70%
Novartis expands development programs for NASH through clinical collaboration with Allergan
18Apr17 06:10 GNW Novartis AG 0.70%
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
06Apr17 06:15 GNW Novartis AG 0.70%
Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
03Apr17 06:15 GNW Novartis AG 0.70%
Novartis drug combination Tafinlar® + Mekinist® receives EU approval for BRAF V600-positive advanced non-small cell lung cancer (NSCLC)
29Mar17 21:00 GNW Novartis AG 0.70%
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
29Mar17 21:00 GNW Novartis AG 0.70%
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
23Mar17 06:15 GNW Novartis AG 0.70%
Alcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correction
22Mar17 06:15 GNW Novartis AG 0.70%
Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
22Mar17 06:15 GNW Novartis AG 0.70%
Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
21Mar17 06:15 GNW Novartis AG 0.70%
Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis
18Mar17 13:45 GNW Novartis AG 0.70%
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
13Mar17 19:08 GNW Novartis AG 0.70%
Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
13Mar17 19:08 GNW Novartis AG 0.70%
Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
13Mar17 06:15 GNW Novartis AG 0.70%
Sandoz announces winners of inaugural Healthcare Access Challenge (Sandoz HACk)
06Mar17 06:15 GNW Novartis AG 0.70%
Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
06Mar17 06:10 GNW Novartis AG 0.70%
New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine
28Feb17 12:44 GNW Novartis AG 0.70%
Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
24Feb17 12:07 GNW Novartis AG 0.70%
Novartis receives positive CHMP opinion for Tafinlar® + Mekinist® in BRAF-positive non-small cell lung cancer (NSCLC) patients
23Feb17 06:15 GNW Novartis AG 0.70%
Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC
31Jan17 06:15 GNW Novartis AG 0.70%
Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC
26Jan17 06:15 GNW Novartis AG 0.70%
Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report
26Jan17 06:10 GNW Novartis AG 0.70%
Alcon launches new trifocal toric intraocular lens for patients with astigmatism undergoing cataract surgery
25Jan17 17:31 GNW Novartis AG 0.70%
NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2016
25Jan17 06:00 GNW Novartis AG 0.70%
Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
25Jan17 06:00 GNW Novartis AG 0.70%
Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
06Jan17 06:15 GNW Novartis AG 0.70%
Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders
20Dec16 06:15 GNW Novartis AG 0.70%
Novartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc.
19Dec16 21:30 GNW Novartis AG 0.70%
Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases
16Dec16 12:27 GNW Novartis AG 0.70%
Novartis receives positive CHMP recommendation for Ilaris® to treat rare diseases in adults and children called Periodic Fever Syndromes
16Dec16 12:23 GNW Novartis AG 0.70%
Novartis drug Votubia® recommended by CHMP for EU approval to treat refractory partial-onset seizures in patients with TSC
16Dec16 06:15 GNW Novartis AG 0.70%
Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited
12Dec16 06:15 GNW Novartis AG 0.70%
Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines
12Dec16 06:00 GNW Novartis AG 0.70%
Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)
12Dec16 06:00 GNW Novartis AG 0.70%
Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)
09Dec16 13:30 GNW Novartis AG 0.70%
Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole
08Dec16 06:15 GNW Novartis AG 0.70%
Novartis' Ultibro® Breezhaler® improved lung function and COPD symptoms after direct switch from previous treatment
07Dec16 06:15 GNW Novartis AG 0.70%
Novartis' Lucentis® received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions
06Dec16 08:45 GNW Novartis AG 0.70%
Novartis announces Zykadia® first-line study results showing 16.6 month progression-free survival in patients with ALK+ advanced NSCLC
05Dec16 18:30 GNW Novartis AG 0.70%
Novartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna® from Glivec®
05Dec16 18:00 GNW Novartis AG 0.70%
Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work
05Dec16 06:15 GNW Novartis AG 0.70%
New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product
04Dec16 00:00 GNW Novartis AG 0.70%
Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL
03Dec16 18:00 GNW Novartis AG 0.70%
Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study
29Nov16 06:15 GNW Novartis AG 0.70%
Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda
21Nov16 06:20 GNW Novartis AG 0.70%
Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)
21Nov16 06:15 GNW Novartis AG 0.70%
Novartis commends publication of major report which recommends broad use of dual bronchodilators to treat COPD
18Nov16 06:15 GNW Novartis AG 0.70%
Innovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originator
16Nov16 06:15 GNW Novartis AG 0.70%
Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer
15Nov16 18:00 GNW Novartis AG 0.70%
New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths
14Nov16 06:20 GNW Novartis AG 0.70%
Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis
14Nov16 06:15 GNW Novartis AG 0.70%
Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain
14Nov16 00:01 GNW Novartis AG 0.70%
Novartis improves ranking in 2016 Access to Medicine Index
01Nov16 06:15 GNW Novartis AG 0.70%
Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer
01Nov16 06:15 GNW Novartis AG 0.70%
Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer
31Oct16 06:15 GNW Novartis AG 0.70%
Novartis Wins Two Prestigious Prix Galien Foundation Awards; Gleevec® recognized as "Discovery of the Decade" for Best Pharmaceutical Product, Cosentyx® as Best Biotechnology Product
25Oct16 06:00 GNW Novartis AG 0.70%
Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
25Oct16 06:00 GNW Novartis AG 0.70%
Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
17Oct16 22:00 GNW Novartis AG 0.70%
Alcon launches the CyPass® Micro-Stent at the American Academy of Ophthalmology (AAO) 2016 annual meeting
09Oct16 07:15 GNW Novartis AG 0.70%
Novartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival beyond 18 months in Phase II study
08Oct16 07:30 GNW Novartis AG 0.70%
Novartis' Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow up
08Oct16 07:15 GNW Novartis AG 0.70%
Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care
03Oct16 06:15 GNW Novartis AG 0.70%
Novartis reports over half of psoriasis patients do not reach the achievable treatment goal of clear skin in largest global survey
01Oct16 06:15 GNW Novartis AG 0.70%
Novartis late-breaking data show Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients
28Sep16 21:30 GNW Novartis AG 0.70%
Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine
28Sep16 06:15 GNW Novartis AG 0.70%
Sandoz invites young entrepreneurs to enter Sandoz HACk, a global competition to help solve healthcare access challenges
23Sep16 16:51 GNW Novartis AG 0.70%
Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions
23Sep16 06:15 GNW Novartis AG 0.70%
Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia® in untreated adult ALK+ NSCLC patients
21Sep16 22:00 GNW Novartis AG 0.70%
Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs
19Sep16 06:15 GNW Novartis AG 0.70%
Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients
18Sep16 21:00 GNW Novartis AG 0.70%
Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients
17Sep16 10:00 GNW Novartis AG 0.70%
Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients
15Sep16 21:30 GNW Novartis AG 0.70%
Novartis presents new positive data at EHMTIC showing AMG 334 significantly reduces monthly migraine days in chronic migraine
15Sep16 06:15 GNW Novartis AG 0.70%
Novartis Foundation showcases progress in leprosy elimination programs at 19th International Leprosy Congress
09Sep16 06:15 GNW Novartis AG 0.70%
New Novartis point of care Niji(TM) System may provide earlier diagnosis of severe allergic asthma and faster treatment decisions
08Sep16 06:15 GNW Novartis AG 0.70%
Alcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experience
03Sep16 06:15 GNW Novartis AG 0.70%
Novartis' Ultibro® Breezhaler® consistently more effective than Seretide®* in reducing COPD flare-ups across different patient groups
31Aug16 06:15 GNW Novartis AG 0.70%
AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment
29Aug16 06:15 GNW Novartis AG 0.70%
Novartis convenes experts to discuss new technologies in healthcare at Novartis International BioCamp
25Aug16 06:15 GNW Novartis AG 0.70%
Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS
25Aug16 06:15 GNW Novartis AG 0.70%
Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS
15Aug16 06:15 GNW Novartis AG 0.70%
Six leading scientists to receive prestigious Novartis Prizes for Immunology at 16th International Congress of Immunology
03Aug16 06:15 GNW Novartis AG 0.70%
Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
02Aug16 06:15 GNW Novartis AG 0.70%
Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma
19Jul16 06:01 GNW Novartis AG 0.70%
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
19Jul16 06:01 GNW Novartis AG 0.70%
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
Date / Time Company % Chg
26May17 20:31 Novartis AG 0.70%
Novartis receives FDA approval for expanded use of Zykadia® in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)
23May17 06:15 Novartis AG 0.70%
Novartis' new analyses reinforce the potential of Ultibro® Breezhaler® for COPD patients historically treated with steroids
19May17 12:47 Novartis AG 0.70%
Novartis receives positive CHMP opinion for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)
18May17 11:05 Novartis AG 0.70%
Novartis data at ASCO, ICML and EHA meetings demonstrate meaningful advancements in cancer care
17May17 06:15 Novartis AG 0.70%
Novartis Foundation and partners launch initiative to tackle hypertension and its root causes in low-income urban communities
11May17 06:15 Novartis AG 0.70%
Novartis celebrates 21st annual Community Partnership Day with over 24,500 associates volunteering in their local communities
04May17 06:15 Novartis AG 0.70%
Novartis exercises exclusive option agreement with Conatus for the treatment of NASH
28Apr17 16:30 Novartis AG 0.70%
Novartis receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM)
26Apr17 06:15 Novartis AG 0.70%
Alcon announces EU launch of CyPass® Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma
25Apr17 06:00 Novartis AG 0.70%
Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
25Apr17 06:00 Novartis AG 0.70%
Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
24Apr17 21:30 Novartis AG 0.70%
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada
24Apr17 06:15 Novartis AG 0.70%
Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS
21Apr17 18:43 Novartis AG 0.70%
Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*
19Apr17 22:00 Novartis AG 0.70%
NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia
18Apr17 06:15 Novartis AG 0.70%
Novartis expands development programs for NASH through clinical collaboration with Allergan
18Apr17 06:10 Novartis AG 0.70%
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
06Apr17 06:15 Novartis AG 0.70%
Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
03Apr17 06:15 Novartis AG 0.70%
Novartis drug combination Tafinlar® + Mekinist® receives EU approval for BRAF V600-positive advanced non-small cell lung cancer (NSCLC)
29Mar17 21:00 Novartis AG 0.70%
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
29Mar17 21:00 Novartis AG 0.70%
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
23Mar17 06:15 Novartis AG 0.70%
Alcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correction
22Mar17 06:15 Novartis AG 0.70%
Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
22Mar17 06:15 Novartis AG 0.70%
Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
21Mar17 06:15 Novartis AG 0.70%
Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis
18Mar17 13:45 Novartis AG 0.70%
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
13Mar17 19:08 Novartis AG 0.70%
Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
13Mar17 19:08 Novartis AG 0.70%
Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
13Mar17 06:15 Novartis AG 0.70%
Sandoz announces winners of inaugural Healthcare Access Challenge (Sandoz HACk)
06Mar17 06:15 Novartis AG 0.70%
Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
06Mar17 06:10 Novartis AG 0.70%
New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine
28Feb17 12:44 Novartis AG 0.70%
Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
24Feb17 12:07 Novartis AG 0.70%
Novartis receives positive CHMP opinion for Tafinlar® + Mekinist® in BRAF-positive non-small cell lung cancer (NSCLC) patients
23Feb17 06:15 Novartis AG 0.70%
Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC
31Jan17 06:15 Novartis AG 0.70%
Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC
26Jan17 06:15 Novartis AG 0.70%
Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report
26Jan17 06:10 Novartis AG 0.70%
Alcon launches new trifocal toric intraocular lens for patients with astigmatism undergoing cataract surgery
25Jan17 17:31 Novartis AG 0.70%
NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2016
25Jan17 06:00 Novartis AG 0.70%
Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
25Jan17 06:00 Novartis AG 0.70%
Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
06Jan17 06:15 Novartis AG 0.70%
Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders
20Dec16 06:15 Novartis AG 0.70%
Novartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc.
19Dec16 21:30 Novartis AG 0.70%
Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases
16Dec16 12:27 Novartis AG 0.70%
Novartis receives positive CHMP recommendation for Ilaris® to treat rare diseases in adults and children called Periodic Fever Syndromes
16Dec16 12:23 Novartis AG 0.70%
Novartis drug Votubia® recommended by CHMP for EU approval to treat refractory partial-onset seizures in patients with TSC
16Dec16 06:15 Novartis AG 0.70%
Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited
12Dec16 06:15 Novartis AG 0.70%
Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines
12Dec16 06:00 Novartis AG 0.70%
Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)
12Dec16 06:00 Novartis AG 0.70%
Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)
09Dec16 13:30 Novartis AG 0.70%
Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole
08Dec16 06:15 Novartis AG 0.70%
Novartis' Ultibro® Breezhaler® improved lung function and COPD symptoms after direct switch from previous treatment
07Dec16 06:15 Novartis AG 0.70%
Novartis' Lucentis® received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions
06Dec16 08:45 Novartis AG 0.70%
Novartis announces Zykadia® first-line study results showing 16.6 month progression-free survival in patients with ALK+ advanced NSCLC
05Dec16 18:30 Novartis AG 0.70%
Novartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna® from Glivec®
05Dec16 18:00 Novartis AG 0.70%
Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work
05Dec16 06:15 Novartis AG 0.70%
New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product
04Dec16 00:00 Novartis AG 0.70%
Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL
03Dec16 18:00 Novartis AG 0.70%
Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study
29Nov16 06:15 Novartis AG 0.70%
Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda
21Nov16 06:20 Novartis AG 0.70%
Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)
21Nov16 06:15 Novartis AG 0.70%
Novartis commends publication of major report which recommends broad use of dual bronchodilators to treat COPD
18Nov16 06:15 Novartis AG 0.70%
Innovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originator
16Nov16 06:15 Novartis AG 0.70%
Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer
15Nov16 18:00 Novartis AG 0.70%
New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths
14Nov16 06:20 Novartis AG 0.70%
Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis
14Nov16 06:15 Novartis AG 0.70%
Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain
14Nov16 00:01 Novartis AG 0.70%
Novartis improves ranking in 2016 Access to Medicine Index
01Nov16 06:15 Novartis AG 0.70%
Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer
01Nov16 06:15 Novartis AG 0.70%
Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer
31Oct16 06:15 Novartis AG 0.70%
Novartis Wins Two Prestigious Prix Galien Foundation Awards; Gleevec® recognized as "Discovery of the Decade" for Best Pharmaceutical Product, Cosentyx® as Best Biotechnology Product
25Oct16 06:00 Novartis AG 0.70%
Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
25Oct16 06:00 Novartis AG 0.70%
Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
17Oct16 22:00 Novartis AG 0.70%
Alcon launches the CyPass® Micro-Stent at the American Academy of Ophthalmology (AAO) 2016 annual meeting
09Oct16 07:15 Novartis AG 0.70%
Novartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival beyond 18 months in Phase II study
08Oct16 07:30 Novartis AG 0.70%
Novartis' Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow up
08Oct16 07:15 Novartis AG 0.70%
Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care
03Oct16 06:15 Novartis AG 0.70%
Novartis reports over half of psoriasis patients do not reach the achievable treatment goal of clear skin in largest global survey
01Oct16 06:15 Novartis AG 0.70%
Novartis late-breaking data show Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients
28Sep16 21:30 Novartis AG 0.70%
Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine
28Sep16 06:15 Novartis AG 0.70%
Sandoz invites young entrepreneurs to enter Sandoz HACk, a global competition to help solve healthcare access challenges
23Sep16 16:51 Novartis AG 0.70%
Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions
23Sep16 06:15 Novartis AG 0.70%
Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia® in untreated adult ALK+ NSCLC patients
21Sep16 22:00 Novartis AG 0.70%
Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs
19Sep16 06:15 Novartis AG 0.70%
Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients
18Sep16 21:00 Novartis AG 0.70%
Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients
17Sep16 10:00 Novartis AG 0.70%
Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients
15Sep16 21:30 Novartis AG 0.70%
Novartis presents new positive data at EHMTIC showing AMG 334 significantly reduces monthly migraine days in chronic migraine
15Sep16 06:15 Novartis AG 0.70%
Novartis Foundation showcases progress in leprosy elimination programs at 19th International Leprosy Congress
09Sep16 06:15 Novartis AG 0.70%
New Novartis point of care Niji(TM) System may provide earlier diagnosis of severe allergic asthma and faster treatment decisions
08Sep16 06:15 Novartis AG 0.70%
Alcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experience
03Sep16 06:15 Novartis AG 0.70%
Novartis' Ultibro® Breezhaler® consistently more effective than Seretide®* in reducing COPD flare-ups across different patient groups
31Aug16 06:15 Novartis AG 0.70%
AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment
29Aug16 06:15 Novartis AG 0.70%
Novartis convenes experts to discuss new technologies in healthcare at Novartis International BioCamp
25Aug16 06:15 Novartis AG 0.70%
Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS
25Aug16 06:15 Novartis AG 0.70%
Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS
15Aug16 06:15 Novartis AG 0.70%
Six leading scientists to receive prestigious Novartis Prizes for Immunology at 16th International Congress of Immunology
03Aug16 06:15 Novartis AG 0.70%
Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
02Aug16 06:15 Novartis AG 0.70%
Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma
19Jul16 06:01 Novartis AG 0.70%
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
19Jul16 06:01 Novartis AG 0.70%
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects